Nestle Takes Aim at Ozempic Market

Nestle logo | Image by Nestle

With the number of people on GLP-1 weight-loss medication expanding, Nestle hopes to cash in on the multi-billion dollar market with some new products, reports Fox 4 KDFW:

“Nestlé is launching a line of food products tailored to people using weight-loss medication in an effort to capitalize on a market expected to reach $30 billion in the next six years.

“Under its new Vital Pursuit brand, the global food giant plans to launch 12 products ranging from frozen protein pasta, sandwich melts and pizzas, all of which are made with a higher amount of protein and essential nutrients like iron, vitamin A and potassium. They are also ‘portion-aligned to a weight loss medication user’s appetite,’ the company said.

“It’s the first time the company, known for brands like DiGiorno pizza, KitKat, and Nesquik, created a food brand that’s specifically intended for glucagon-like peptide 1 (GLP-1) users. GLP-1 agonists are a class of Type 2 diabetes drugs that improves blood sugar control but may also lead to weight loss. Semaglutide, which is the active ingredient in Novo Nordisk’s Wegovy and Ozempic, as well as tirzepatide, which is the active ingredient in Eli Lily’s Mounjaro and Zepbound, are considered GLP-1 drugs.”

To read the entire article on Fox 4 KDFW, please click HERE.

Support our non-profit journalism

Submit a Comment

Your email address will not be published. Required fields are marked *

Continue reading on the app
Expand article